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Recent reports have demonstrated a decline in bacterial bloodstream infections (BSIs) fol-
lowing adherence to central line insertion practices; however, declines have been less evi-
dent for BSIs due to Candida species.
Methods
We conducted active, population-based laboratory surveillance for candidemia in metropoli-
tan Atlanta, GA and Baltimore, MD over a 5-year period. We calculated annual candidemia
incidence and antifungal drug resistance rates.
Results
We identified 3,848 candidemia cases from 2008–2013. Compared with 2008, candidemia in-
cidence per 100,000 person-years decreased significantly by 2013 in both locations (GA: 14.1
to 9.5, p<0.001; MD: 30.9 to 14.4, p<0.001). A total of 3,255 cases (85%) had a central ve-
nous catheter (CVC) in place within 2 days before the BSI culture date. In both locations, the
number of CVC-associated cases declined (GA: 473 to 294; MD: 384 to 151).Candida albi-
cans (CA, 36%) andCandida glabrata (CG, 27%) were the most common species recovered.
In both locations, the proportion of cases with fluconazole resistance decreased (GA: 8.0% to
7.1%, −10%; MD: 6.6% to 4.9%, −25%), while the proportion of cases with an isolate resistant
to an echinocandin increased (GA: 1.2% to 2.9%, +147%; MD: 2.0% to 3.5%, +77%). Most
(74%) echinocandin-resistant isolates were CG; 17 (<1%) isolates were resistant to both drug
categories (multidrug resistant [MDR], 16/17 were CG). The proportion of CG cases with MDR
Candida increased from 1.8% to 2.6%.
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Conclusions
We observed a significant decline in the incidence of candidemia over a five-year period,
and increases in echinocandin-resistant and MDR Candida. Efforts to strengthen infection
control practices may be preventing candidemia among high-risk patients. Further surveil-
lance for resistant Candida is warranted.
Introduction
Many healthcare-associated infections (HAIs), including some types of bloodstream infections
(BSIs), are a preventable cause of morbidity and mortality in healthcare facilities. In an effort to
reduce HAIs, the adoption of new healthcare policies, such as those tied to Medicare reim-
bursement, have incentivized reducing infection rates and produced mixed results [1–6].
BSIs caused by Candida species, also known as candidemia, remain an important public
health problem [7–9]. Recent reports have documented significant declines in some bacterial
central line associated bloodstream infections (CLABSIs) following adherence to established
central line insertion practices, however, similar declines have been less evident for CLABSIs
due to Candida species [10–14]. Candida spp. are common gastrointestinal flora and while
many Candida BSIs can be attributed to the presence of a central line, some Candida spp. are
also hypothesized to cause infections by translocation across the gastrointestinal tract unrelated
to central line insertion practices [15, 16]. Therefore, line insertion bundles developed to re-
duce CLABSIs alone may not be completely effective in reducing Candida BSIs.
In 2012, we reported a substantial increase over a twenty-year period in the overall popula-
tion-based incidence of candidemia using population-based surveillance for candidemia in two
U.S. locations [9, 17]. This surveillance system captures all culture-confirmed BSIs caused by
Candida spp., not just healthcare-associated CLABSIs that are tied to mandatory reporting and
reimbursement policies, and provide a more complete picture of the burden of candidemia in
these communities. The earlier report also noted a marked shift in the species distribution
among causative organisms with a significant increase in Candida glabrata (CG), a species
more likely to be resistant to azoles, the standard antifungal drug of choice.
To monitor more recent changes in the incidence of candidemia and antifungal drug resis-
tance, we now report trends over a five-year surveillance period using population-based pro-




Surveillance for candidemia was conducted among residents of Atlanta, Georgia (Fulton,
DeKalb, Cobb, Gwinnett, Clayton, Douglas, Newton, and Rockdale counties; 25 hospitals, pop-
ulation: 3.8 million) and Baltimore City and County, Maryland (15 hospitals, population: 1.4
million). Data were collected for five years at each location (March 1, 2008—February 28, 2013
in Atlanta; June 1, 2008—May 31, 2013 in Baltimore).
Surveillance methods
The methods of surveillance have been previously described [9]. Briefly, a case of candidemia
was defined as a blood culture positive for a Candida species collected from a resident of the
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surveillance area at least 30 days apart from any other blood culture positive for Candida spp.
Cases were classified as: (1) hospital-onset (HO) if the first culture was obtained>3 days after
admission (with admission being day 1), (2) healthcare-associated community-onset (HACO) if
the culture was obtained3 days after admission in a patient with recent healthcare exposure,
or (3) community-associated (CA) if the culture was obtained as an outpatient or3 days of
admission in a patient without documentation of recent healthcare exposure. Basic demo-
graphic and clinical information was collected on all cases. Surveillance personnel used stan-
dardized case report forms to abstract data from medical records. Laboratory records from all
participating laboratories were audited monthly.
Isolate collection, identification, and antifungal susceptibility testing
All available isolates were sent to CDC for species confirmation and antifungal drug suscepti-
bility testing; testing methods have been previously described [18]. CDC-confirmed species are
reported; if no isolate was received at CDC, local laboratory species identifications are reported.
Because in vitro susceptibility testing may demonstrate susceptibility to one echinocandin but
resistance to another that is of questionable clinical correlation [19], molecular testing was
used to confirm that the majority of the CG isolates with in vitro echinocandin resistance had a
mutation that has been associated with clinical failure [20].
Statistical methods and denominators
Incidence rates were calculated using year specific population estimates for Baltimore [21] and
Atlanta [22] and are presented per 100,000 person-years. Age-adjusted incidence rates did not
vary substantially over the five year surveillance period from crude rates, and thus we report
crude annual incidence rates of candidemia.
Categorical variables were analyzed using chi-square tests or Fisher’s exact tests. We used a
Poisson regression model adjusting for age group to evaluate the change in overall and species
specific annual incidence rates over the 5 year surveillance period. In all analyses, the level of
significance was set at α = 0.05. All analyses were done using SAS software (version 9.3, SAS In-
stitute, Inc., Cary, NC).
Human subjects
Patient data were de-identified at each site prior to access and analysis by CDC. CDC con-
ducted ethical review of this surveillance project and deemed it a non-research activity. This ac-
tivity was also evaluated individually at each location, and was either deemed a public health
assessment or human subjects research, and approved by local review boards. In the Baltimore
area, the Maryland Department of Health and Mental Hygiene's Institutional Review Board re-
viewed and approved the protocol, and the protocol was determined exempt from review by
the Johns Hopkins Bloomberg School of Public Health Institutional Review Board. In the At-
lanta area, the protocol was reviewed and approved by the Emory University Institutional Re-
view Board, and the protocol was determined exempt from review by the Georgia Department
of Public Health Review Board.
Results
Case-Patient Characteristics
During the 5-year surveillance period, we detected 3,848 cases of candidemia: 2,324 (60%) in
the Atlanta area (ATL) and 1,524 (40%) in Baltimore City and County (BTM, Table 1). The
median age was 58 years (range, 1 day—101 years), 1,992 (52%) were male, and 2,200 (60%)
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were black. Candida albicans (CA) was the most common species recovered (1,401 cases, 36%),
followed by Candida glabrata (CG, 27%), Candida parapsilosis (CP, 15%), Candida tropicalis
(CT, 9%), and other species (6%), and 6% of cases had>1 species recovered from their initial
blood culture. A total of 225 (7%) cases had an isolate that was resistant to fluconazole including
110/1049 (10%) CG. Fifty-five (2%) cases had an isolate that was resistant to an echinocandin in-
cluding 43/1049 (4%) CG; 17 (<1%) cases had an isolate that was multidrug resistant (MDR), de-
fined as resistant to fluconazole and one or more echinocandins. Of the MDR cases, 16/17 (94%)
were CG, representing 1.5% (16/1049) of CG isolates; 7/17 (44%) MDR cases occurred among
persons without documented echinocandin exposure in the previous 14 days.
Changes in Incidence Rates
Crude annual incidence rates per 100,000 person-years are illustrated in Fig. 1. Compared with
2008 (year 1), the incidence of candidemia decreased significantly in both locations: in ATL, in-
cidence rates declined 33% from 14.1/100,000 from the first year of surveillance to 9.5/100,000
by year 5 (p<0.001). In BTM, incidence rates declined 54% from 30.9/100,000 from year 1 to
14.4/100,000 by year 5 (p<0.001).
Table 1. Selected characteristics of patients with candidemia in Atlanta and Baltimore metropolitan areas.
Atlanta Baltimore Total
Characteristic n (%) n (%) n (%)
Cases 2324 (60) 1524 (40) 3848 (100)
Median Age, years (range) 58 (1 d-101 yrs) 58 (1 d-98 yrs) 58 (1 d-101 yrs)
Male sex 1196 (52) 796 (52) 1992 (52)
Black race 1427 (61) 873 (57) 2300 (57)
CVC in place
All ages 1991 (86) 1264 (83) 3255 (85)
Age <1 year 55 (72) 34 (92) 89 (79)
Age > = 65 666 (80) 434 (76) 1100 (78)
Resistance to fluconazole 136 (07) 89 (06) 225 (07)
Resistance to an echinocandin 26 (01) 29 (02) 55 (02)
Resistance to both flu and
echino*
8 (<1) 9 (<1) 17* (<1)
Species
C. albicans 921 (40) 480 (32) 1401 (36)
C. glabrata 589 (25) 460 (30) 1049 (27)
C. parapsilosis 390 (17) 204 (13) 594 (15)
C. tropicalis 191 (08) 174 (11) 365 (09)
C. krusei 38 (02) 15 (01) 53 (01)
>1 species 100 (04) 110 (07) 210 (06)
C. dubliniensis 16 (01) 41 (03) 57 (02)
Other 76 (03) 38 (03) 114 (03)
Age groups, n (incidence rate per 100,000 person years)
<1 year 76 (28.1) 37 (39.5) 113 (33.8)
1–19 years 88 (1.7) 33 (2.0) 121 (1.9)
20–44 years 429 (6.1) 298 (11.9) 727 (9.0)
45–64 years 899 (19.1) 574 (30.0) 1473 (24.6)
> = 65 years 832 (51.2) 576 (60.1) 1408 (55.7)
*16/17 isolates were C. glabrata species
doi:10.1371/journal.pone.0120452.t001
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Infants aged<1 year and adults aged65 years had the highest rates of candidemia out of
all age groups (infants: 33.8/100,000; adults: 55.7/100,000; Table 1). Analysis of age-specific in-
cidence rates per 100,000 person-years demonstrated a decline in every age group except
among persons aged 1–19 years in BTM, which increased 17% (from 2.0/100,000 in year 1 to
2.4/100,000 in year 5); all other age groups demonstrated a decline (Fig. 2 and Fig. 3). In ATL,
the decline was greatest for persons aged<1 year (from 41.7 to 16.6, −60% decline), followed
by persons aged65 years (from 61.3 to 36.0, −41%,) and aged 45–64 years (from 21.7 to 15.1,
−30%) (Fig. 2). In BTM, the decline was greatest for persons aged 20–44 years (from 19.7 to
6.6, −67%), followed by persons aged 45–64 years (from 42.7 to 19.6, −54%),65 years (from
87.4 to 43.3, −50%) and<1 year (from 51.9 to 32.0, −38%) (Fig. 3).
Hospital-specific Declines
Among 40 hospitals under surveillance, 85% reported either a decrease or no change in the fre-
quency of cases over the surveillance period (Fig. 4). Additionally, of the eight hospitals that
contributed at least 100 cases during the 5 years of surveillance, there was a substantial drop in
the number of cases identified: in ATL 319 cases were identified in the first year, and 190 were
identified in the last year (−40%); in BTM, 282 cases were identified in the first year and 125
were identified in the last year (−56%).
High Risk Groups
In both locations, the frequency of hospital onset (HO) and healthcare-associated community
onset (HACO) cases decreased, but community-associated (CA) did not: in ATL, HO cases de-
clined from 405 in year 1 to 226 in year 5 (−44%), HACO declined from 124 to 111 (−10%),
and CA changed from 12 to 14 (+17%);. In BTM, HO cases declined from 253 to 111 (−56%),
HACO dropped from 175 to 79 (−55%), and CA changed from 12 to 15 (+25%) (Table 2).
Among the 135 CA cases, 58 (43%) had diabetes (49% in ATL; 35% in BTM).
A total of 3,255 cases (85%) had a central venous catheter (CVC) in place within 2 days
prior to the date of their initial culture positive for Candida spp. (Table 1). In ATL, CVC-asso-
ciated cases (n = 1,991) declined from 473 (87%) in year 1 to 294 (84%) in year 5 (−38%)
(p = 0.030); in BTM, the number of cases with a CVC declined from 384 (87%) to 151 (74%)
Fig 1. Annual candidemia incidence rates per 100,000 person-years, by year and location, 2008–2013.
doi:10.1371/journal.pone.0120452.g001
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Fig 2. Annual candidemia incidence rates per 100,000 person-years, by year and age-group in the Metropolitan Baltimore area.
doi:10.1371/journal.pone.0120452.g002
Fig 3. Annual candidemia incidence rates per 100,000 person-years, by year and age-group in the Metropolitan Atlanta area.
doi:10.1371/journal.pone.0120452.g003
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(−61%) (p<0.001) (Fig. 5). The number of non-CVC-associated cases declined in ATL from 68
(13%) to 57 (16%); and in BTM from 56 (13%) to 53 (26%).
Changes in species distribution
Species-specific incidence rates of all species decreased from year 1 to year 5 in both locations
except for CT in ATL, which increased 4% (from 0.71/100,000 to 0.73/100,000, Table 2). In
ATL, CA had the largest drop in incidence (from 5.91/100,000 in year 1 to 3.72/100,000 in year
5, −37%), followed by CG (from 4.28 to 2.86, −33%), and CP (from 2.38 to 1.63, −31%). In
BTM, CP had the greatest drop in incidence (from 5.41 to 1.47, −73%), followed by CA (from
11.6 to 5.12, −56%), and CG (from 9.34 to 4.97, −47%).
Change in antifungal drug resistance
In both locations, the overall percent of cases with an isolate resistant to fluconazole decreased
(ATL: from 8.0% to 7.1%, −10%; BTM: from 6.6% to 4.9%, −25%), while the overall percent of
cases with an isolate resistant to an echinocandin increased (ATL: from 1.2% to 2.9%, +147%;
BTM: from 2.0% to 3.5%, +77%; Table 2); 41 (75%) isolates resistant to an echinocandin were
CG; other echinocandin-resistant species included CA (n = 7), CT (n = 3), CP (n = 2), and CD
(n = 1). The proportion of CG cases due to multi-drug resistant (MDR) Candida, increased
from 1.8% in 2008 to 2.6% in 2013.
Fig 4. Changes in candidemia case count at participating hospitals over the five-year study period (2008–2013), by the total number of cases each
hospital contributed during the study.
doi:10.1371/journal.pone.0120452.g004
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Table 2. Selected characteristics of candidemia patients by year of surveillance, in Atlanta (ATL) and Baltimore (BTM)metropolitan areas.
Characteristic Y1 Y2 Y3 Y4 Y5 Change
Total Cases
ATL 541 526 487 419 351 −35%
BTM 440 354 323 202 205 −53%
Crude Incidence Rate
ATL 14.1 13.5 13.2 11.4 9.5 −33%
BTM 30.9 24.8 22.7 14.2 14.4 −54%
Patient group (n)
ATL HO 405 374 335 270 226 −44%
HACO 124 135 136 128 111 −10%
CA 12 17 16 21 14 17%
BTM HO 253 223 182 121 111 −56%
HACO 175 122 131 72 79 −55%
CA 12 9 10 9 15 25%
Central Venous Catheter within 2 days of candidemia (n)
ATL All ages 473 454 421 349 294 −38%
<1 year of age 14 22 6 4 9 −36%
> = 65 years of age 159 138 158 118 93 −42%
BTM All ages 384 312 262 155 151 −61%
<1 year of age 10 9 6 3 6 −40%
> = 65 years of age 136 114 77 58 49 −64%
Surgery among patients who did not have a CVC (n)
ATL Ab surgery 11 6 6 9 6 −45%
Non ab surgery 7 4 6 6 7 0%
BTM Ab surgery 6 11 10 6 6 0%
Non ab surgery 7 5 3 5 7 0%
Species-Specific Incidence Rates (IR)
ATL CA 5.91 5.73 5.59 4.86 3.72 −37%
CG 4.28 3.62 3.35 2.72 2.86 −33%
CP 2.38 2.62 2.39 2.25 1.63 −31%
CT 0.71 0.80 1.22 0.90 0.73 4%
CK 0.27 0.26 0.19 0.19 0.25 −8%
Other 0.42 0.54 0.70 0.38 0.46 8%
BTM CA 11.60 9.18 7.72 4.56 5.12 −56%
CG 9.34 8.14 8.20 5.68 4.97 −47%
CP 5.41 4.07 3.51 1.69 1.47 −73%
CT 3.53 3.03 3.15 1.33 1.97 −44%
CK 0.43 0.37 0.14 0.14 0.28 −35%
Other 0.93 0.99 1.20 0.47 0.69 −26%
% Resistant to Fluconazole
ATL 8% 9.38% 5.67% 7% 7.14% −10%
BTM 6.57% 8.07% 4.73% 4.50% 4.93% −25%
% Resistant to an Echinocandin
ATL 1.18% 1.44% 0.99% 0.83% 2.92% 147%
BTM 1.95% 0.58% 2.21% 2.50% 3.45% 77%
% Multidrug Resistant Candida
ATL 0.18% 0.38% 0% 0.48% 0.85% 372%
BTM 0.91% 0% 0.62% 0.50% 0.98% 8%
Note: HO, healthcare onset. HACO, healthcare-associated community-onset. CA, community-acquired. Ab surgery, abdominal surgery. Y, year.
doi:10.1371/journal.pone.0120452.t002
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Discussion
This report from the largest U.S. population-based surveillance program for candidemia to
date describes a significant decline in the overall incidence of candidemia in two metropolitan
regions. This decline was seen in almost all age groups, was primarily among patients with
healthcare exposure, and was especially notable among cases with a central venous catheter.
Importantly, we also report an increase in echinocandin resistance as well as the emergence of
multi-drug resistant Candida BSIs.
In 2012, we reported an increase in candidemia incidence over a twenty year period, as seen
through two periodic measurements using population-based surveillance [9], that was attribut-
ed to multifactorial changes in patient populations, including possible increases in patient pop-
ulations at high risk for candidemia.
In comparison, our current report documents a subsequent decrease in incidence that is not
likely to be due to changes in high-risk populations; rather, it is probable that the declines
noted here are related to healthcare delivery improvements. We found that declines were pre-
dominantly among candidemia cases with healthcare exposure, but not among the small num-
ber of community-associated cases, suggesting that factors associated with healthcare delivery
may be driving this decline. Our data further demonstrate declines among patients with Candi-
da BSIs occurring in the presence of CVCs, while the number of cases without CVCs did not
decline as substantially. Taken together, these data suggest that the large declines noted here
may be the result of policies and practices related to catheter insertion and maintenance.
Recent policies targeted at reducing healthcare-associated infections, including state man-
dates for public reporting, have incentivized reducing CLABSIs [1]. Subsequent reports includ-
ing data from CDC’s National Health Safety Network (NHSN) have described large declines in
CLABSI rates [13, 23, 24]. Data from our active surveillance system, which is not tied to any
Fig 5. Candidemia cases that had a CVC compared with cases that had no CVC, in Atlanta (ATL) and Baltimore (BTM), 2008–2013.
doi:10.1371/journal.pone.0120452.g005
Declining Incidence of Candidemia
PLOS ONE | DOI:10.1371/journal.pone.0120452 March 30, 2015 9 / 12
reimbursement or reporting mechanism, support the trends observed through systems such as
NHSN and suggest these declines are robust. Anecdotally, most hospitals in our surveillance
area have recently introduced policies that mandate improvements in catheter care (data not
shown); further study is needed to understand if declines can be attributed to these policies.
Notably, while we documented a drop in fluconazole resistance, we also report a small but
concerning increase in isolates resistant to echinocandins, and the emergence of multidrug re-
sistant (MDR) Candida, almost all of which were the species CG. Although the decrease in flu-
conazole resistance is reassuring, it may be partially due to the increased use of echinocandins
as primary therapy for candidemia. This shift in practice, particularly for CG infections, may
be contributing to the increase in echinocandin resistance; recent reports have demonstrated
the emergence of echinocandin resistant CG[17, 25, 26], possibly driven by wider usage of this
drug class as primary therapy[27] and prophylaxis. Although the modes of action and target
sites of the triazoles (i.e. fluconazole) and echinocandins are different[28], CG are the most
common fluconazole-resistant species, and mutations conferring echinocandin resistance in
CG can emerge quickly[29]. Microbiology laboratories should consider antifungal susceptibili-
ty testing for CG isolates, since detection of echinocandin-resistant or MDR Candida can
influence therapy.
It is also concerning that 44% of MDR Candida occurred in patients without recent expo-
sure to echinocandins. This observation suggests person-to-person transmission of this resis-
tant phenotype is possible, as has been previously suggested [30]. Vigilant monitoring for
resistance among CG species will continue to be critical, and further investigation into the pos-
sible transmission of MDR Candida will be essential for targeting prevention efforts.
This report is subject to several limitations. Although we suspect that the dramatic declines
in candidemia occurring in patients with a CVC were due to improved catheter care, it is possi-
ble that declines were due to some external factor such as reductions in overall CVC usage in a
particular ward. We report large declines in most hospitals under surveillance, but do not col-
lect data on number of hospital admissions or other hospital denominator data, and are there-
fore unable to report if the declines are a true decrease in the risk of disease or if this is related
to a shift in healthcare utilization (e.g., change in central line utilization, referral patterns, fre-
quency of blood culture collection, etc). However, the majority of hospitals in our surveillance
system demonstrated declines indicating a trend not isolated to a few institutions.
This report describes significant declines in the incidence of candidemia bloodstream infec-
tions in two major U.S. locations over a 5 year period, and an increase in echinocandin resistant
CG. Continued surveillance will be important to help understand factors contributing to these
declines and to monitor for the emergence of resistant Candida.
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